Kevin Laubscher

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2012 · 458 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma

Ahmad A. Tarhini, Michael Millward, Paul N. Mainwaring et al. · Cancer · 2009 · 121 citations

Medicine, Immunology, Oncology +15

The Clinical Course of Treated and Untreated Gaucher Disease. A Study of 45 Patients

Ernest Beutler, Anna Demina, Kevin Laubscher et al. · Blood Cells Molecules and Diseases · 1995 · 111 citations

Medicine, Internal Medicine, Pharmacotherapy +3

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

Brian C. Goh, Nandi J. Reddy, Uday B. Dandamudi et al. · Clinical Pharmacology & Therapeutics · 2010 · 84 citations

Medicine, Pharmacokinetics, Pharmacology +16

Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma

Matthew S. Davids, Amanda Charlton, Swee-Siang Ng et al. · Journal of Clinical Oncology · 2009 · 81 citations

Medicine, Oncology, Pharmacology +12